HUNTSVILLE, Ala., Aug. 2 /PRNewswire/ -- Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery and validation, today announced the release of the newest generation of shRNAmir libraries with its Expression Arrest(TM) TRIPZ(TM) inducible lentiviral shRNAmir library for RNAi. Targeting the entire human genome with multiple shRNAmir constructs per gene, the TRIPZ inducible lentiviral shRNAmir library builds on Open Biosystems' proven vector-based RNAi technologies that enable researchers to quickly realize the inherent value of vector-based RNAi. This offering for inducible RNAi, the first of its kind, allows for rapid validation of drug targets by the creation of in vivo animal models, a necessary step in the drug discovery process.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070423/CLM143LOGO )
The TRIPZ library consists of shRNAmir constructs that have been pre- cloned into a Tetracycline-inducible lentiviral vector, resulting in a powerful RNAi trigger that expands the potential of RNAi to cell and animal models previously refractory to RNAi. Open Biosystems' TRIPZ shRNAmir provides researchers and scientists with options for tightly regulated RNAi and increased delivery range into a vast number of cell types from primary and non-dividing cells to in vivo animal models.
"Inducible Lentiviral shRNAmir takes RNAi research to the next level. The new TRIPZ(TM) inducible shRNAmir makes it possible to both analyze the effect of gene knockdown as well as validate that result in the same experiment. Open Biosystems continues to arm the research community with leading edge technologies necessary to propel and sustain biological research," said Gwen Fewell, PhD, Product Manager for RNAi at Open Biosystems.
Expression Arrest human TRIPZ lentiviral shRNAmir is available immediately as individual shRNAmir constructs, target gene sets or a whole genome library subscription. For additional information about the human TRIPZ inducible lentiviral shRNAmir library, please contact firstname.lastname@example.org.
About Open Biosystems
Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit: www.openbiosystems.com .
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070423/CLM143LOGO
PRN Photo Desk, email@example.comOpen Biosystems, Inc.
CONTACT: Gwen D. Fewell, PhD, of Open Biosystems Inc., +1-256-319-1489,firstname.lastname@example.org